Peter Forsyth, MD
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,342 of the $22,877 with a category attached, or 67.1%. 10 manufacturers reported payments, led by BTG International Inc. at 27.0% of the total. Reporting peaked in 2019 at $13,493 and has fallen 99.4% since, to $86 in 2025.
Across 26 payments — averaging $879.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BTG International Inc.$6K
- Bristol Myers Squibb$5K
- Boehringer Ingelheim$4K
- Daiichi Sankyo Inc.$3K
- Bayer$2K
- Boehringer Ingelheim International GmbH$2K
- plus $484 from 4 others
Across 53 payments — averaging $43,666 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$897K
- Pfizer$622K
- Bristol Myers Squibb$595K
- E.r. Squibb & Sons, L.L.C.$200K
What the payments were for
- Consulting fees$15,34267%
- Speaking & faculty fees$5,23123%
- Travel & lodging$1,3266%
- Food & beverage$9684%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BTG International Inc. | 5 | $6,187 |
| Bristol Myers Squibb | 3 | $4,966 |
| Boehringer Ingelheim | 1 | $4,165 |
| Daiichi Sankyo Inc. | 2 | $2,954 |
| Bayer | 5 | $2,196 |
| Boehringer Ingelheim International GmbH | 2 | $1,927 |
| Clinigen, Inc. | 2 | $302 |
| AbbVie | 4 | $86 |
| Novartis | 1 | $85 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,877 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VimpatLacosamide | 12 | $13,489 |
| Levetiracetam | 49 | $3,046 |
| Lacosamide | 24 | $2,484 |
| Pentoxifylline | 28 | $620 |
| Methylphenidate Hcl | 18 | $185 |
| Dexamethasone | 11 | $90 |
| Pregabalin | 12 | $48 |
| Escitalopram Oxalate | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other neurology in Tampa
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Mark CascioneTampa$1.2M
- Tuan VuTampa$1M
- Katherine StandleyTampa$735K
- Susan SteenTampa$341K
- Rossitza ChichkovaTampa$294K
- Brody HenkelTampa$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.